RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$176.43
+0.58%Oct 13, 2026, 11:30 UTC
Repligen announced that it will report its third-quarter 2026 financial results on October 27, 2026.
Source:Oct 6, 2026, 13:05 UTC
Repligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., a developer and supplier of cell processing tools and services for the cell and gene therapy market.
Source:Oct 5, 2026, 22:29 UTC
Freshworks Inc. will replace BioLife Solutions Inc. in the S&P SmallCap 600 index effective before the open of trading on Thursday, October 8, 2026.
Source:Sep 15, 2026, 20:07 UTC
Karen A. Dawes will retire from the board of directors of Repligen Corp, effective September 30, 2026.
Sep 8, 2026, 22:00 UTC
Repligen and BioLife Solutions received US antitrust approval for their $1.5 billion merger as the Hart-Scott-Rodino waiting period expired on September 3, 2026.
Source:Aug 22, 2026, 07:58 UTC
B. Metzler seel. Sohn & Co. AG acquired a new position of 26,361 shares in Repligen Corporation, valued at approximately $3.60 million, during the second quarter, as disclosed in its SEC filing.
Source:Aug 6, 2026, 20:03 UTC
Repligen announced it will acquire BioLife Solutions, with the transaction expected to close in the fourth quarter of 2026.
Source:Aug 1, 2026, 07:50 UTC
Avidity Partners Management LP increased its stake in Repligen Corporation by 54.7% during the second quarter of 2026, acquiring an additional 27,500 shares, according to a Form 13F filing.
Source:Jul 28, 2026, 11:00 UTC
Repligen Corporation reported financial results for the second quarter of 2026, covering the three-month period ended June 30, 2026.
Jul 22, 2026, 10:00 UTC
Repligen agreed to acquire BioLife Solutions to expand its cell therapy capabilities with biopreservation media.
Jun 27, 2026, 16:20 UTC
BioLife has drawn takeover interest from Repligen.